Related Experiment Video

Updated: Feb 28, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer

Wensong Wei1, Yufeng Zou1, Qihua Jiang1

  • 1Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.

The International Journal of Biological Markers
|June 18, 2017
PubMed
Abstract

Insights

Triple-negative breast cancer (TNBC) shows high proteasome activity. Targeting proteasome subunit beta 5 (PSMB5) may improve TNBC treatment and patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
  • Lack of therapeutic markers limits treatment options for TNBC patients.
  • Current targeted therapies are not fully effective for TNBC.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying TNBC.
  • To identify key molecular targets for TNBC therapy.
  • To investigate the role of specific genes in TNBC development.

Main Methods:

  • Gene Set Enrichment Analysis (GSEA) applied to microarray data.
  • Screening for significantly altered functional modules in TNBC.
  • Association study of candidate genes with TNBC progression.

Main Results:

  • Significant proteasome activation observed in TNBC.
  • Proteasome subunit beta 5 (PSMB5) is overexpressed in TNBC.
  • PSMB5 overexpression correlates with poor prognosis in TNBC patients.
  • PSMB5 knockdown induces apoptosis and enhances sensitivity to bortezomib and paclitaxel.

Conclusions:

  • PSMB5 plays a crucial role in TNBC development.
  • PSMB5 is a potential prognostic biomarker for TNBC.
  • PSMB5 represents a promising therapeutic target for TNBC.
Keywords:
BortezomibPaclitaxelProteasome subunit beta 5 (PSMB5)TNBCTriple-negative breast cancer

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.6K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K